Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

Schedule of Segment Reporting Information, by Segment

The following table summarizes information for our single reportable segment, including significant segment expenses:


	Three Months Ended March 31,
	2026		2025
Revenue	$	19,799	$	12,729
Less:
Cost of sales	3,577		2,225
Early-stage research and development(1)	1,266		990
Late-stage research and development(1)	2,244		1,744
Marketing, selling, and administrative	2,934		2,468
Acquired in-process research and development	584		1,572
Other segment items(2)	1,798		971
Net income	$	7,396	$	2,759

Interest expense	$	332	$	244
Expenditures for long-lived assets(3)	2,438		1,517

(1) Early-stage research and development primarily includes costs incurred from discovery through Phase 2 clinical trials. Late-stage research and development primarily includes costs incurred from Phase 3 clinical trials.

(2) Other segment items primarily include income taxes.

(3) Includes expenditures for property and equipment and computer software costs.